Navigating the Pharmaceutical Contract Development Market: Comprehensive Report on Strategy, Business Prospects, Growth Trends, and Competitive Dynamics by 2026
In January 2023, Catalent supported the manufacturing of Sarepta’s most advanced gene therapy candidate, delandistrogene moxeparvovec (SRP-9001), to treat Duchenne muscular dystrophy.
View full press release